KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Cost of Revenue (2017 - 2025)

Amneal Pharmaceuticals (AMRX) has 9 years of Cost of Revenue data on record, last reported at $517.1 million in Q4 2025.

  • For Q4 2025, Cost of Revenue fell 70.78% year-over-year to $517.1 million; the TTM value through Dec 2025 reached $1.9 billion, down 38.04%, while the annual FY2025 figure was $1.9 billion, 7.44% up from the prior year.
  • Cost of Revenue reached $517.1 million in Q4 2025 per AMRX's latest filing, up from $510.5 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $1.8 billion in Q4 2024 and bottomed at -$945.8 million in Q4 2021.
  • Average Cost of Revenue over 5 years is $400.7 million, with a median of $400.1 million recorded in 2023.
  • Peak YoY movement for Cost of Revenue: plummeted 171.51% in 2021, then skyrocketed 48761.17% in 2024.
  • A 5-year view of Cost of Revenue shows it stood at -$945.8 million in 2021, then skyrocketed by 250.62% to $1.4 billion in 2022, then dropped by 16.36% to $1.2 billion in 2023, then soared by 48.51% to $1.8 billion in 2024, then plummeted by 70.78% to $517.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cost of Revenue were $517.1 million in Q4 2025, $510.5 million in Q3 2025, and $438.3 million in Q2 2025.